Vanguard Global Infrastructure ETF (VBLD) Stock Price, News, Quotes-Moomoo

AU ETFDetailed Quotes

VBLD Vanguard Global Infrastructure ETF

Watchlist

65.920
-0.130-0.20%

20min DelayMarket Closed Jul 26 15:53 AET

66.210High65.810Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

NextEra Energy Partners Downgraded at Wolfe Research
Seeking Alpha14:47 ET · Ratings
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Benzinga13:00 ET
Union Pacific GAAP EPS of $2.74 Beats by $0.03, Revenue of $6B Misses by $60M
Seeking AlphaJul 25 07:48 ET
US Stocks Suffered a 'Black Wednesday': How to Hedge Risks in Market Turbulence?
Moomoo News GlobalJul 25 07:24 ET · Previews
U.S. Weekly Rail Traffic Rises 1.4% Year-over-year
Seeking AlphaJul 24 17:58 ET
Union Pacific Q2 2024 Earnings Preview
Seeking AlphaJul 24 13:35 ET

Comments

Moomoo AI

Oct 17, 2023 02:08

The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.

Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Moomoo AI

Oct 17, 2023 02:04

Matthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.

Press Release: VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

Moomoo AI

Oct 17, 2023 02:04

EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.

Press Release: VBL Therapeutics Selected for EUR17.5 Million of Funding from Horizon Europe EIC Accelerator Program